Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal Transplantation for Inflammatory Bowel Disease
NCT02391012Phase 1Terminated
- Sponsor
- Meir Medical Center
- Start
- Apr 2015
- Primary completion
- Jun 2016
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fecal microbiome transplant in ulcerative colitis (UC) and Crohn's disease, sponsored by Meir Medical Center. Primary endpoint: Improvement of disease activity index at 4 weeks. Started Apr 2015; status: terminated.
02
Drugs
fecal microbiome transplant
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT02391012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02391012.